Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report)’s share price reached a new 52-week high during trading on Tuesday . The company traded as high as $495.55 and last traded at $491.22, with a volume of 949961 shares. The stock had previously closed at $481.67.
Wall Street Analyst Weigh In
Several research firms recently commented on ALNY. Chardan Capital lifted their price objective on Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the stock a “buy” rating in a report on Friday, August 1st. Wells Fargo & Company raised their price target on shares of Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the company an “equal weight” rating in a report on Friday, August 1st. Wall Street Zen cut shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Sunday, October 12th. Bank of America boosted their target price on shares of Alnylam Pharmaceuticals from $453.00 to $520.00 and gave the company a “buy” rating in a research note on Wednesday, September 17th. Finally, UBS Group increased their price target on Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the company a “buy” rating in a report on Friday, August 1st. Twenty-three analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $466.92.
Alnylam Pharmaceuticals Stock Up 2.0%
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last announced its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The company had revenue of $773.69 million for the quarter, compared to analysts’ expectations of $633.54 million. During the same period last year, the firm earned ($0.13) EPS. Alnylam Pharmaceuticals’s revenue for the quarter was up 17.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.
Insider Activity at Alnylam Pharmaceuticals
In related news, Director Michael W. Bonney sold 11,250 shares of the stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $450.00, for a total value of $5,062,500.00. Following the completion of the sale, the director directly owned 16,804 shares of the company’s stock, valued at approximately $7,561,800. This represents a 40.10% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Jeffrey V. Poulton sold 3,821 shares of the firm’s stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total transaction of $1,727,283.05. Following the sale, the executive vice president owned 54,052 shares in the company, valued at approximately $24,434,206.60. The trade was a 6.60% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 98,144 shares of company stock worth $44,160,261 in the last quarter. 1.20% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Alnylam Pharmaceuticals
A number of institutional investors have recently bought and sold shares of the business. OFI Invest Asset Management boosted its stake in shares of Alnylam Pharmaceuticals by 5.8% in the third quarter. OFI Invest Asset Management now owns 403 shares of the biopharmaceutical company’s stock worth $184,000 after acquiring an additional 22 shares during the period. Meridian Financial Advisors LLC lifted its holdings in Alnylam Pharmaceuticals by 3.5% in the 3rd quarter. Meridian Financial Advisors LLC now owns 828 shares of the biopharmaceutical company’s stock worth $378,000 after purchasing an additional 28 shares in the last quarter. Evelyn Partners Investment Management LLP boosted its stake in Alnylam Pharmaceuticals by 11.5% in the 2nd quarter. Evelyn Partners Investment Management LLP now owns 290 shares of the biopharmaceutical company’s stock worth $95,000 after purchasing an additional 30 shares during the period. Daiwa Securities Group Inc. grew its holdings in Alnylam Pharmaceuticals by 0.3% during the 2nd quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock valued at $4,220,000 after buying an additional 35 shares in the last quarter. Finally, Sowell Financial Services LLC raised its position in shares of Alnylam Pharmaceuticals by 6.2% during the third quarter. Sowell Financial Services LLC now owns 654 shares of the biopharmaceutical company’s stock valued at $298,000 after buying an additional 38 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.
Featured Articles
- Five stocks we like better than Alnylam Pharmaceuticals
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet
- What is the S&P/TSX Index?
- 3 High-Yield Banks for Investors to Buy on the Dip
- Short Selling – The Pros and Cons
- 5 Surprising Stocks Set to Benefit From a Future Robotics Boom
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.